share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake

SEC announcement ·  May 2 17:45
Summary by Moomoo AI
Blake Borgeson, a key figure at Recursion Pharmaceuticals, completed a sale of 11,447 shares of the company's Class A Common Stock on April 30, 2024. The transaction was carried out on the open market at a price of $7.9465 per share, resulting in a total sale value of approximately $90,963.59. Following the sale, Borgeson's direct holdings in Recursion Pharmaceuticals amount to 7,218,414 shares. This sale reflects a transaction in the company's stock that could be of interest to current and potential investors.
Blake Borgeson, a key figure at Recursion Pharmaceuticals, completed a sale of 11,447 shares of the company's Class A Common Stock on April 30, 2024. The transaction was carried out on the open market at a price of $7.9465 per share, resulting in a total sale value of approximately $90,963.59. Following the sale, Borgeson's direct holdings in Recursion Pharmaceuticals amount to 7,218,414 shares. This sale reflects a transaction in the company's stock that could be of interest to current and potential investors.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more